TG Therapeutics raises FY26 revenue guidance to $1 billion
TG Therapeutics beat Q3 revenue expectations and raised full-year guidance, fueled by strong BRIUMVI sales and positive clinical data.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed